Author:
Arnould L,Gelly M,Penault-Llorca F,Benoit L,Bonnetain F,Migeon C,Cabaret V,Fermeaux V,Bertheau P,Garnier J,Jeannin J-F,Coudert B
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C (2004) Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31: 51–57
2. Bines J, Murad A, Lago S, Ferrari B, Andrade J, Filho EA (2003) Weekly docetaxel (Taxotere®) and trastuzumab (Herceptin®) as primary therapy in stage III HER-2 overexpressing breast cancer – a Brazilian multicenter study. Breast Cancer Res Treat 82 (Supplement 1): S56 (abstract 243)
3. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46–53
4. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685
5. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31: 3016–3025
Cited by
465 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献